Search

Your search for "vvos" returned the following results.
Filter Results:
InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q2, YTD 2023 Financial, Operational Report

August 17, 2023

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from a variety of health conditions, many of which are associated with breathing related sleep conditions arising from certain dentofacial abnormalities, is reporting its financial and operating results for the second quarter and six-month […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Date for Rescheduled Q2 2023 Financial Results Conference Call

August 16, 2023

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from a variety of health conditions, many of which are associated with breathing related sleep conditions arising from certain dentofacial abnormalities, has announced the date for the conference call to discuss financial results for […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Plans to Reschedule Q2 2023 Financial Results Conference Call

August 15, 2023

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from a variety of health conditions, many of which are associated with breathing related sleep conditions arising from certain dentofacial abnormalities, has rescheduled its conference call to discuss financial results for the second quarter […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Plans to Release Q2 2023 Financial Numbers, Schedules Conference Call

August 11, 2023

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from a variety of health conditions, many of which are associated with breathing-related sleep issues arising from certain dentofacial abnormalities, anticipates releasing its second quarter 2023 financial results on Aug. 14, 2023, after the […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q1 2023 Financial Numbers, Corporate Update

June 9, 2023

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from a variety of health conditions, many of which are associated with breathing-related sleep issues arising from certain dentofacial abnormalities, has released a financial report and company update for the first quarter, the period […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Plans to Release Q1 2023 Financial Numbers, Host Earnings Call

June 7, 2023

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from a variety of health conditions, many of which are associated with breathing-related sleep issues arising from certain dentofacial abnormalities, anticipates releasing its first quarter 2023 financial results on June 8, 2023, after the […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Featured in Proactive Studio Podcast

May 16, 2023

Vivos Therapeutics (NASDAQ: VVOS) chairman and CEO Kirk Huntsman recently joined Natalie Stoberman from the Proactive Studio to discuss how the company’s POD device performed a highly effective rate in treating migraine headaches in a clinical study. During the interview, Huntsman said that the study showed 92% of patients reporting complete resolution of their symptoms, […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces New Strategic Initiatives

May 9, 2023

Vivos Therapeutics (NASDAQ: VVOS) today announced it has implemented a broad set of initiatives aimed at improving operational efficiencies, reducing expenses and positioning Vivos to take advantage of current growth opportunities. According to the update, the initiatives touch most aspects of Vivos’ operations and include expense reductions, product suite expansion and organizational changes that included […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Reports on ‘Game-Changing’ Appliance Treatment for Migraines

May 1, 2023

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from a variety of health conditions, many of which are associated with breathing related sleep issues arising from certain dentofacial abnormalities, is reporting on the results of a recent clinical observational study. According to […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q4, FY Financial and Operational Report

March 31, 2023

Vivos Therapeutics (NASDAQ: VVOS), a medical device and technology company that delivers training and a full line of highly effective proprietary oral appliances for the treatment of breathing related sleep disorders in adults, including mild-to-moderate obstructive sleep apnea (“OSA”) and snoring, is reporting its financial results and operating highlights for the fourth quarter and full […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Schedules Release of Q4 and FY 2022 Results, Conference Call

March 30, 2023

Vivos Therapeutics (NASDAQ: VVOS) is a medical device and technology company that delivers training and a full line of highly effective proprietary oral appliances for the treatment of breathing related sleep disorders in adults. The company announced plans to release its fourth quarter and full year 2022 financial results after market close today, Thursday, March […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) to Participate at 35th Annual ROTH Conference

March 8, 2023

Vivos Therapeutics (NASDAQ: VVOS) is a medical device and technology company that delivers training and a full line of highly effective proprietary oral appliances for the treatment of breathing-related sleep disorders in adults. The company today announced that its chairman and CEO Kirk Huntsman and CFO Brad Amman will participate at the 35th Annual ROTH […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Expands Product Portfolio, Revenue Potential Through Strategic Acquisition

March 1, 2023

Vivos Therapeutics (NASDAQ: VVOS), a medical device and technology company that delivers training and a full line of highly effective proprietary oral appliances for the treatment of breathing related sleep disorders, today announced its acquisition of certain U.S. and international patents, product rights and other miscellaneous intellectual property from Advanced Facialdontics LLC (“AFD”), which holds […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Participation at Emerging Growth Conference

February 22, 2023

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”) and snoring in adults, will be presenting at today’s Emerging Growth Conference. The company announced that chair and CEO Kirk Huntsman will be participating in the conference; Huntsman’s […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Regains Compliance with Nasdaq Listing Requirements

January 20, 2023

Vivos Therapeutics (NASDAQ: VVOS) is focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild-to-moderate obstructive sleep apnea (“OSA”) and snoring in adults. The company today announced its receipt of a notice from the listing qualifications department of the Nasdaq Stock Market informing Vivos it has regained compliance with the minimum bid […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Closing of $8M Private Placement

January 10, 2023

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring in adults, has closed on its previously announced private placement. The placement was with a single institutional investor and resulted in approximately $8 million in gross […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Enters into Private Placement Agreement

January 5, 2023

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring in adults, has entered into a definitive agreement. According to the announcement, the agreement is with a single institutional investor and is estimated to raise $8 […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces FDA Clearance of Proprietary Oral Appliance for Obstructive Sleep Apnea Treatment

January 4, 2023

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (“OSA”) and snoring in adults, has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) for its own daytime-nighttime appliance (“DNA”). According to the announcement, the clearance for […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q2, Q3 Financial Report, Operational Update

December 21, 2022

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring in adults, is reporting on its second and third quarter of 2022. According to the company, the filing, which includes financial results along with operation highlights, […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Reports on Q2 Q3 2022 Financial Results, Announces Conference Call

December 16, 2022

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring in adults, anticipates releasing its second and third quarter 2022 financial results on Dec. 20, 2022. The information will be released after market close. The company […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Creates Strategic Medical Billing Partnership, New Revenue Stream

December 15, 2022

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring in adults, announced a new strategic medical billing partnership with Nexus Dental Systems. According to the announcement, Vivos anticipates that the partnership will generate new revenue […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Receives NASDAQ Notification Regarding Q3 Quarterly Report Filing

November 29, 2022

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring in adults, has received a compliance notice from the Listing Qualifications Department of the Nasdaq Stock Market. The notice was regarding the fact that Vivos has […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Update on Revenue Recognition Review

November 22, 2022

Vivos Therapeutics (NASDAQ: VVOS) is a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild-to-moderate obstructive sleep apnea (“OSA”) and snoring in adults. The company today provided an update on its review of its revenue recognition policies and the expected timing for the release of its second and […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Q2 Earnings Delay

August 23, 2022

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring in adults, has reported a delay in releasing its Q2 2022 financial earnings. The company reported that its independent registered public accountants noted a possible need […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) to Reschedule Release of Q2 2022 Financial Results

August 15, 2022

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring in adults, has announced that it will be rescheduling the release of its Q2 2022 financial results, which is for the period ended June 30, 2022; […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Q2 2022 Call to Discuss Financial Results

August 9, 2022

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring in adults, will release its second quarter 2022 financial results on Aug. 15, 2022, after market close. In conjunction with that, the company has also scheduled […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Receives Regulatory Clearances in Australia for Line of Oral Appliances

July 14, 2022

Vivos Therapeutics (NASDAQ: VVOS), a revenue-generating medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring in adults, has been cleared to treat obstructive sleep apnea in Australia; the clearance allows the company to treat all ages, regarding of severity. The […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Enters Strategic Distribution Agreement with GM Instruments

June 29, 2022

Vivos Therapeutics (NASDAQ: VVOS) is a revenue-stage medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (“OSA”) and snoring in adults. The company today announced its entry into an exclusive agreement with GM Instruments Ltd. for the distribution of GM Instruments’ NR6 Rhinomanometer, […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Presents Sleep Apnea Study Results at Annual SLEEP 2022 Event

June 14, 2022

Vivos Therapeutics (NASDAQ: VVOS), a revenue-generating medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (“OSA”) and snoring in adults, shared results from its retrospective study during SLEEP 2022, the annual meeting of the Associated Professional Sleep Societies. Vivos Medical Advisory Board member […]

Press Releases

Correlate Infrastructure Partners Inc. Announces Its Application to Uplist to the NASDAQ Exchange

June 1, 2022

BOISE, Idaho, June 01, 2022 (GLOBE NEWSWIRE) — via InvestorWire — Correlate Infrastructure Partners Inc. (OTCQB: CIPI) (“Correlate” or the “Company”), a technology-enabled energy optimization and clean energy solutions provider for the U.S. commercial real estate industry, is pleased to announce it has begun the application process for uplisting to the Nasdaq Exchange from the OTCQB. Correlate continues […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Participation in Annual SLEEP 2022 Event

May 26, 2022

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring in adults, will be attending and presenting at SLEEP 2022. The event is the annual meeting of the Associated […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q1 2021 Financial, Operational Report

May 17, 2022

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (“OSA”) and snoring in adults, is reporting its financial results and operating highlights for the first quarter ended March 31, 2022. Highlights […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Schedules Release of Q1 2022 Results, Conference Call

April 28, 2022

Vivos Therapeutics (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (“OSA”) and snoring in adults. The company today announced plans to release its financial results for the first quarter ended March […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Opens Third US Multidisciplinary Sleep Apnea Clinic

April 26, 2022

Vivos Therapeutics (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (“OSA”) and snoring. The company today announced that Vivos’ medical integration division will open its third U.S. multidisciplinary sleep apnea clinic […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q4, Full-Year 2021 Financial, Operational Report

April 1, 2022

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (“OSA”) and snoring in adults, is reporting its financial results and operating highlights for the fourth quarter and full year ended Dec. […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Call to Review Q4, FY 2021 Financial Results

March 31, 2022

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild-to-moderate obstructive sleep apnea (“OSA”) and snoring, has scheduled a conference call to discuss financial results that will be reported today after market close. The financial results will […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Selected Among ‘World’s Most Innovative Companies’ by Fast Company Magazine

March 8, 2022

Vivos Therapeutics (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (“OSA”) and snoring. Vivos Therapeutics today announced that Fast Company magazine has selected Vivos and its novel and proprietary technology for […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Rebrands Proprietary Offering of Clinical Treatment Devices, Modalities and Protocols

March 3, 2022

Vivos Therapeutics (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (“OSA”) and snoring. The company today announced a rebranding of its proprietary offering of clinical treatment devices, modalities and protocols, now […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Plans to Participate in Investor Conferences

March 2, 2022

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild-to-moderate obstructive sleep apnea (“OSA”) and snoring, will be presenting at two upcoming investor conferences. According to the company, VVOS CEO Kirk Huntsman will participate in the Q1 […]

InvestorNewsBreaks

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) to Participate in 2022 World Sleep Congress

February 24, 2022

Vivos Therapeutics (NASDAQ: VVOS) Medical Advisor Board has been invited to present at the upcoming World Sleep Congress. The event, slated for March 11–16, 2022, will be held in Rome. Members of the board will be presenting a summary review of sleep-therapy data from patients treated with the Vivos Method. Vivos is a medical technology […]

No ResultsNo content matches your search/filter.

 

 

 

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).